Ingrid López-Reyna
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ingrid López-Reyna has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Yajaira Valentine Jimenez-Antolinez
Universidad Autonóma de Nuevo León
4 shared publications - David Gómez-Almaguer
Hematology Service, Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León (UANL), Monterrey, Nuevo León, México
3 shared publications - Julia Esther Colunga Pedraza
Department of Hematology, Dr. José Eleuterio González University Hospital, School of Medicine, Autonomous University of Nuevo León, Monterrey, Mexico and Francisco I. Madero Pte., s/n, and Gonzalitos Avenue, Colonia Mitras Centro, Monterrey, NL, Mexico
3 shared publications - Oscar González-Llano
Universidad Autonóma de Nuevo León
3 shared publications - Perla Rocío Colunga Pedraza
Servicio de Hematología, Hospital Universitario Dr José Eleuterio González, UANL, Monterrey, Mexico
3 shared publications - Andrés Gómez-De León
Hematology Service, Hospital Universitario “Dr. José Eleuterio González”, Universidad Autonoma de Nuevo León, Monterrey, Mexico
2 shared publications
Latest Publications
- 12 May 2026
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
High-Dose methotrexate in pediatric acute lymphoblastic leukemia: Variability across Mexican centers from a national survey
Introduction: High-dose methotrexate (HD-MTX) is a cornerstone of pediatric acute lymphoblastic leukemia (ALL) therapy. It's safe administration requires timely pharmacokinetic monitoring and comprehensive supportive care, which are frequently limited in low- and middle-income countries (LMICs). In Mexico, variability in HD-MTX practices may compromise treatment safety and efficacy. This study aimed to characterize national practice patterns and identify context-specific adaptations in the delivery of HD-MTX in resource constrained settings. Methods: A nationwide, cross-sectional electronic survey was conducted between May and November 2023 among pediatric hematologists and oncologists treating patients younger than 18 years with ALL. The questionnaire assessed institutional guidelines, availability of pharmacokinetic monitoring, and supportive care practices, including hydration, urinary alkalinization, and folinic acid rescue. Data were analyzed descriptively. Results: A total of 111 specialists from 27 Mexican states participated. Only 56% reported having institutional HD-MTX guidelines. While 97% administered HD-MTX to high-risk ALL patients, only 61% used full protocol-recommended doses, and nearly one-third reported dose reductions. Methotrexate plasma level monitoring was only available in 56% of centers. Most centers (86%) administered HD-MTX exclusively in the inpatient setting. Supportive care practices varied substantially across institutions and risk groups. Reported barriers included limited laboratory capacity (61%), lack of standardized protocols (44%), and delays related to bed availability (39%). Conclusions: Optimizing HD-MTX delivery in Mexico requires integrating standardized clinical practices with targeted system-level interventions to ensure timely access to pharmacokinetic monitoring. The development and implementation of context-adapted national guidelines may improve safety, reduce variability in care, and mitigate outcome disparities in children with ALL.
- 12 May 2026
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
High-Dose methotrexate in pediatric acute lymphoblastic leukemia: Variability across Mexican centers from a national survey
Introduction: High-dose methotrexate (HD-MTX) is a cornerstone of pediatric acute lymphoblastic leukemia (ALL) therapy. It's safe administration requires timely pharmacokinetic monitoring and comprehensive supportive care, which are frequently limited in low- and middle-income countries (LMICs). In Mexico, variability in HD-MTX practices may compromise treatment safety and efficacy. This study aimed to characterize national practice patterns and identify context-specific adaptations in the delivery of HD-MTX in resource constrained settings. Methods: A nationwide, cross-sectional electronic survey was conducted between May and November 2023 among pediatric hematologists and oncologists treating patients younger than 18 years with ALL. The questionnaire assessed institutional guidelines, availability of pharmacokinetic monitoring, and supportive care practices, including hydration, urinary alkalinization, and folinic acid rescue. Data were analyzed descriptively. Results: A total of 111 specialists from 27 Mexican states participated. Only 56% reported having institutional HD-MTX guidelines. While 97% administered HD-MTX to high-risk ALL patients, only 61% used full protocol-recommended doses, and nearly one-third reported dose reductions. Methotrexate plasma level monitoring was only available in 56% of centers. Most centers (86%) administered HD-MTX exclusively in the inpatient setting. Supportive care practices varied substantially across institutions and risk groups. Reported barriers included limited laboratory capacity (61%), lack of standardized protocols (44%), and delays related to bed availability (39%). Conclusions: Optimizing HD-MTX delivery in Mexico requires integrating standardized clinical practices with targeted system-level interventions to ensure timely access to pharmacokinetic monitoring. The development and implementation of context-adapted national guidelines may improve safety, reduce variability in care, and mitigate outcome disparities in children with ALL.
- 1 February 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (2) , e2500469
Optimizing Blinatumomab Access for Low- and Middle-Income Countries: Feasibility of a Shortened, Vial-Sharing, Outpatient Approach for Pediatric ALL
PURPOSE: This study aims to evaluate the safety, feasibility, effectiveness, and cost-saving potential of a shortened, vial-sharing outpatient blinatumomab regimen for treating relapsed or refractory (R/R) ALL in children. MATERIALS AND METHODS: We conducted a retrospective study of pediatric patients with R/R B-cell ALL (B-ALL) treated with a shortened outpatient blinatumomab regimen (<21 days), aiming to achieve a negative measurable residual disease (MRD) remission before hematopoietic stem-cell transplantation (HSCT). RESULTS: Twelve patients were included: three (25%) with primary refractory disease and nine (75%) with relapse. The median follow-up time was 33 months (range, 10-76 months). Blinatumomab was administered for a median of 19 days (range, 11-21), with 75% (9 of 12) of patients completing treatment entirely on an outpatient basis. Five patients (62%) achieved CR with undetectable MRD, and all four patients who initiated treatment because of persistent MRD achieved MRD clearance (100%). Ten patients (83%) proceeded to haploidentical HSCT. The estimated 3-year overall survival (OS) was 54%, and the relapse-free survival (RFS) was 44%. These optimization measures resulted in a 43% reduction in drug-related expenditures. CONCLUSION: Reduced-duration outpatient blinatumomab shows promise as a context-adapted strategy for heavily pretreated pediatric patients with ALL. Given the small retrospective cohort, these findings should be interpreted with caution.
- 1 February 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (2) , e2500469
Optimizing Blinatumomab Access for Low- and Middle-Income Countries: Feasibility of a Shortened, Vial-Sharing, Outpatient Approach for Pediatric ALL
PURPOSE: This study aims to evaluate the safety, feasibility, effectiveness, and cost-saving potential of a shortened, vial-sharing outpatient blinatumomab regimen for treating relapsed or refractory (R/R) ALL in children. MATERIALS AND METHODS: We conducted a retrospective study of pediatric patients with R/R B-cell ALL (B-ALL) treated with a shortened outpatient blinatumomab regimen (<21 days), aiming to achieve a negative measurable residual disease (MRD) remission before hematopoietic stem-cell transplantation (HSCT). RESULTS: Twelve patients were included: three (25%) with primary refractory disease and nine (75%) with relapse. The median follow-up time was 33 months (range, 10-76 months). Blinatumomab was administered for a median of 19 days (range, 11-21), with 75% (9 of 12) of patients completing treatment entirely on an outpatient basis. Five patients (62%) achieved CR with undetectable MRD, and all four patients who initiated treatment because of persistent MRD achieved MRD clearance (100%). Ten patients (83%) proceeded to haploidentical HSCT. The estimated 3-year overall survival (OS) was 54%, and the relapse-free survival (RFS) was 44%. These optimization measures resulted in a 43% reduction in drug-related expenditures. CONCLUSION: Reduced-duration outpatient blinatumomab shows promise as a context-adapted strategy for heavily pretreated pediatric patients with ALL. Given the small retrospective cohort, these findings should be interpreted with caution.
- Open Access
- 12 September 2025
- Published by Elsevier in Annals of Hepatology
- Vol. 31 (2) , 102116
Situational panorama of chronic liver diseases: A single-center experience at a university hospital in northeast Mexico (1995–2019)
- 12 September 2025
- Published by Elsevier in Annals of Hepatology
- Vol. 31 (2) , 102116
Open AccessSituational panorama of chronic liver diseases: A single-center experience at a university hospital in northeast Mexico (1995–2019)
- Open Access
- 18 August 2024
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 46 (Suppl 6) , S193-S201
Overcoming challenges to reduce time to antibiotic therapy in febrile neutropenic children: insights from a Mexican center
- 18 August 2024
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 46 (Suppl 6) , S193-S201
Open AccessOvercoming challenges to reduce time to antibiotic therapy in febrile neutropenic children: insights from a Mexican center
- Open Access
- 2 November 2023
- Published by American Society of Hematology in Blood
- Vol. 142 (Supplement) , 6054
CRLF2 Expression in Mexicans with Acute Lymphoblastic Leukemia across the Age Spectrum
Disclosures. Gomez-Almaguer:Novartis: Honoraria; Janssen: Consultancy, Honoraria; AMGEN: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria. Gomez-De Leon:A
- 2 November 2023
- Published by American Society of Hematology in Blood
- Vol. 142 (Supplement) , 6054
Open AccessCRLF2 Expression in Mexicans with Acute Lymphoblastic Leukemia across the Age Spectrum
Disclosures. Gomez-Almaguer:Novartis: Honoraria; Janssen: Consultancy, Honoraria; AMGEN: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria. Gomez-De Leon:A
- Open Access
- 2 November 2023
- Published by American Society of Hematology in Blood
- Vol. 142 (Supplement) , 5813
Exploring the Efficacy and Feasibility of Outpatient Blinatumomab Short Cycles in Pediatric Patients with Relapsed/Refractory B-ALL in LMIC: Preliminary Results
Disclosures. Gomez-Almaguer:AMGEN: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Novartis: Honoraria; AbbVie: Consultancy, Honoraria.Figure 1
- 2 November 2023
- Published by American Society of Hematology in Blood
- Vol. 142 (Supplement) , 5813
Open AccessExploring the Efficacy and Feasibility of Outpatient Blinatumomab Short Cycles in Pediatric Patients with Relapsed/Refractory B-ALL in LMIC: Preliminary Results
Disclosures. Gomez-Almaguer:AMGEN: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Novartis: Honoraria; AbbVie: Consultancy, Honoraria.Figure 1